Aprotinin does not Impair Vascular Function in Patients Undergoing
                    Coronary Artery Bypass Graft Surgery

Josephine Tolkmitt; Heike Brendel; Birgit Zatschler; Stefan Brose; Coy Brunssen; Irakli Kopaliani; Andreas Deussen; Klaus Matschke; Henning Morawietz

doi:10.1055/a-1984-0255

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2023; 55(01): 65-74
DOI: 10.1055/a-1984-0255

Original Article: Endocrine Research

Aprotinin does not Impair Vascular Function in Patients Undergoing Coronary Artery Bypass Graft Surgery

Autor*innen

Josephine Tolkmitt

¹Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
Heike Brendel

¹Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
Birgit Zatschler

²Institute of Physiology, Technische Universität Dresden, Dresden, Germany
Stefan Brose

³Department of Cardiac Surgery, University Heart Center Dresden, Technische Universität Dresden, Dresden, Germany
Coy Brunssen

⁴Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
Irakli Kopaliani

²Institute of Physiology, Technische Universität Dresden, Dresden, Germany
Andreas Deussen

²Institute of Physiology, Technische Universität Dresden, Dresden, Germany
Klaus Matschke

³Department of Cardiac Surgery, University Heart Center Dresden, Technische Universität Dresden, Dresden, Germany
Henning Morawietz

¹Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany

Abstract

Bleeding is a major complication in coronary artery bypass graft surgery. Antifibrinolytic agents like serine protease inhibitor aprotinin can decrease postoperative bleeding and complications of cardiac surgery. However, the effects of aprotinin on vascular function are not completely elucidated. We compared the ex vivo vascular function of left internal mammary arteries from patients undergoing coronary artery bypass graft surgery with and without intraoperative application of aprotinin using a Mulvany Myograph. Human internal mammary arteries were treated with aprotinin ex vivo and tested for changes in vascular function. We analyzed the impact of aprotinin on vascular function in rat aortic rings. Finally, impact of aprotinin on expression and activity of endothelial nitric oxide synthase was tested in human endothelial cells. Intraoperative application of aprotinin did not impair ex vivo vascular function of internal mammary arteries of patients undergoing coronary artery bypass graft surgery. Endothelium-dependent and -independent relaxations were not different in patients with or without aprotinin after nitric oxide synthase blockade. A maximum vasorelaxation of 94.5%±11.4vs. 96.1%±5.5% indicated a similar vascular smooth muscle function in both patient groups (n=13 each). Long-term application of aprotinin under physiological condition preserved vascular function of the rat aorta. In vitro application of increasing concentrations of aprotinin on human endothelial cells resulted in a similar expression and activity of endothelial nitric oxide synthase. In conclusion, intraoperative and ex vivo application of aprotinin does not impair the endothelial function in human internal mammary arteries and experimental models.

Key words

aprotinin - coronary artery bypass graft surgery - endothelial cells - nitric oxide - vascular function

Volltext

Referenzen

References
1 Jimenez Rivera JJ, Iribarren JL, Raya JM. et al. Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study. J Cardiothorac Surg 2007; 2: 17
2 Howell N, Senanayake E, Freemantle N. et al. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2013; 145: 234-240
3 Waldow T, Krutzsch D, Wils M. et al. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass. Clin Hemorheol Microcirc 2009; 42: 269-277
4 Sodha NR, Boodhwani M, Bianchi C. et al. Aprotinin in cardiac surgery. Expert Rev Cardiovasc Ther 2006; 4: 151-160
5 Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-983
6 Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80: 1013-1018
7 Royston D, Bidstrup BP, Taylor KM. et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-1291
8 Smith CR. Management of bleeding complications in redo cardiac operations. Ann Thorac Surg 1998; 65: S2-S8
9 Mangano DT, Tudor IC, Dietzel C. et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365
10 Schneeweiss S, Seeger JD, Landon J. et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771-783
11 Shaw AD, Stafford-Smith M, White WD. et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784-793
12 Fergusson DA, Hebert PC, Mazer CD. et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331
13 Kristeller JL, Roslund BP, Stahl RF. Benefits and risks of aprotinin use during cardiac surgery. Pharmacotherapy 2008; 28: 112-124
14 European Medicines Agency 2013. https://www.ema.europa.eu/en/documents/referral/questions-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-tranexamic-acid_en.pdf; Accessed September 18, 2013
15 Hebert PC, Fergusson DA, Hutton B. et al. Regulatory decisions pertaining to aprotinin may be putting patients at risk. CMAJ 2014; 186: 1379-1386
16 Walkden GJ, Verheyden V, Goudie R. et al. Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Med 2013; 39: 1808-1817
17 Royston D, De Hert S, van der Linden J. et al. A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med 2017; 36: 97-102
18 Benedetto U, Altman DG, Gerry S. et al. Safety of perioperative aprotinin administration during isolated coronary artery bypass graft surgery: insights from the ART (Arterial Revascularization Trial). J Am Heart Assoc 2018; 7: e007570
19 Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109: 1007-1009
20 Ishizawa K, Izawa Y, Ito H. et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005; 46: 1046-1052
21 Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009; 5: 89-100
22 Hofmann A, Brunssen C, Wolk S. et al. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection?. J Am Heart Assoc 2020; 9: e013803
23 Morawietz H, Rueckschloss U, Niemann B. et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902
24 Niemann B, Rohrbach S, Miller MR. et al. Oxidative stress and cardiovascular risk: obesity, diabetes, smoking, and pollution: Part 3 of a 3-Part series. J Am Coll Cardiol 2017; 70: 230-251
25 Punch E, Klein J, Diaba-Nuhoho P. et al. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 2022; 11: e023328
26 Siow RC, Li FY, Rowlands DJ. et al. Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 2007; 42: 909-925
27 Sealey JE, Atlas SA, Laragh JH. et al. Activation of a prorenin-like substance in human plasma by trypsin and by urinary kallikrein. Hypertension 1979; 1: 179-189
28 Derkx FH, Bouma BN, Schalekamp MP. et al. An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 1979; 280: 315-316
29 Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Lond) 1998; 94: 505-509
30 Hill GE, Springall DR, Robbins RA. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 1997; 121: 449-455
31 Cybularz M, Langbein H, Zatschler B. et al. Endothelial function and gene expression in perivascular adipose tissue from internal mammary arteries of obese patients with coronary artery disease. Atheroscler Suppl 2017; 30: 149-158
32 Morawietz H, Erbs S, Holtz J. et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006; 114: I296-I301
33 Zatschler B, Dieterich P, Muller B. et al. Improved vessel preservation after 4 days of cold storage: experimental study in rat arteries. J Vasc Surg 2009; 50: 397-406
34 Riedel K, Deussen AJ, Tolkmitt J. et al. Estrogen determines sex differences in adrenergic vessel tone by regulation of endothelial beta-adrenoceptor expression. Am J Physiol Heart Circ Physiol 2019; 317: H243-H254
35 Goettsch C, Goettsch W, Brux M. et al. Arterial flow reduces oxidative stress via an antioxidant response element and Oct-1 binding site within the NADPH oxidase 4 promoter in endothelial cells. Basic Res Cardiol 2011; 106: 551-561
36 Schubert A, Cattaruzza M, Hecker M. et al. Shear stress-dependent regulation of the human beta-tubulin folding cofactor D gene. Circ Res 2000; 87: 1188-1194
37 Giebe S, Hofmann A, Brux M. et al. Comparative study of the effects of cigarette smoke versus next generation tobacco and nicotine product extracts on endothelial function. Redox Biol 2021; 47: 102150
38 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45
39 Allen S, Anastasiou N, Royston D. et al. Effect of aprotinin on vascular reactivity of coronary bypass grafts. J Thorac Cardiovasc Surg 1997; 113: 319-326
40 Veres G, Radovits T, Schultz H. et al. Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg 2007; 32: 340-345
41 Ulker S, Cinar MG, Bayraktutan U. et al. Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. Cardiovasc Res 2001; 50: 589-596
42 Ulker S, McKeown PP, Bayraktutan U. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res 2002; 55: 830-837
43 Pruefer D, Makowski J, Dahm M. et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg 2003; 75: 210-215
44 Asimakopoulos G, Lidington EA, Mason J. et al. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 2001; 122: 123-128
45 Day JR, Taylor KM, Lidington EA. et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2006; 131: 21-27
46 Day JR, Punjabi PP, Randi AM. et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110: 2597-2600
47 Julius U, Schatz U, Tselmin S. et al. COVID-19 and lipid disorders. Horm Metab Res 2022; 54: 514-521
48 Redondo-Calvo FJ, Padin JF, Munoz-Rodriguez JR. et al. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. Eur J Clin Invest 2022; 52: e13776